Lataa...
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
Radium-223 dichloride (Ra-223) is the first α-particle emitting radiopharmaceutical to be approved for the treatment of patients with castration-resistant prostate cancer and associated bone metastases, and the first bone-targeting agent to significantly improve patient overall survival whilst reduc...
Tallennettuna:
| Julkaisussa: | Int J Urol Nurs |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Blackwell Publishing Ltd
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4467240/ https://ncbi.nlm.nih.gov/pubmed/26097500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijun.12059 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|